Descripción del proyecto
Avances en la administración oral de fármacos
Los ácidos y enzimas del sistema digestivo del estómago, así como la incapacidad de un fármaco para atravesar la barrera de la membrana intestinal, pueden dificultar la administración eficaz de los fármacos orales, sobre todo los fármacos a base de proteínas o péptidos. El equipo del proyecto FREJA, financiado con fondos europeos, tiene como objetivo superar estos retos mediante el diseño y el desarrollo de métodos novedosos que protejan los principios activos hasta que alcancen el lugar adecuado en el intestino del paciente. Esto incluirá el desarrollo de dispositivos autoconfigurables y de proximidad, que administran fármacos al incrustarse en el tejido intestinal (principalmente insulina para pacientes diabéticos). La labor del proyecto dará lugar a una nueva tecnología transferible que permitirá administrar vacunas en forma de comprimido.
Objetivo
Oral delivery of protein/peptide drugs is extremely challenging and the majority of research in the field is based on exploring new formulations, for instance using permeation enhancers. In recent years, some research has been done on ingestible devices for internal injections. Here I propose an entirely new approach based on what we have named ‘Self-configurable, Proximity Enabling Devices’ (SPEDs). The idea is that these devices (the simplest ones will be rolled-up foils) will unfold in the gut, embed in the mucus layer and align to the intestinal wall. It is essential that the SPED has close proximity to the intestinal wall and is retained for a while in order to ensure efficient drug delivery. The proximity will additionally allow us to study and explore the influence of nanotextures (embedded in the SPED) on the interaction with the intestinal wall as well as micromotor-based delivery. The SPEDs will be developed and characterized with the following specific objectives: (i) understanding the SPED properties needed to penetrate mucus, (ii) investigating the mechanisms for enhanced retention time, (iii) exploring the SPED as a carrier for self-propelling cargo, (iv) unraveling the overall behaviour of SPED and (v) demonstrating anti-diabetic drug formulation delivery with at least 5 % systemic uptake and show feasibility of a wider range of applications (delivering/seeding e.g. peptide and proteins/vaccines/probiotics). The work will include simulations of soft materials, device design, micro/nano fabrication, development and use of techniques for mechanical characterisation of device/tissue interaction, bio imaging and in vitro and in vivo studies. The major novelty lies in the SPED concept, providing tissue alignment/contact and unidirectional drug release. Further, the SPEDs provide a unique platform for studies on micromotors as well as nanotextures interaction with the epithelium.
Palabras clave
Programa(s)
- HORIZON.1.1 - European Research Council (ERC) Main Programme
Régimen de financiación
HORIZON-ERC - HORIZON ERC GrantsInstitución de acogida
2800 Kongens Lyngby
Dinamarca